R. Shah (U.K.): Drug-induced révolution of the QT Interval: Why the regulatory concern?
D. Escande (France): Preclinical in vivo strategies to identify the risk of an NCE to prolong the QT interval in man.
F. de Clerck (Belgium): In vivo measurement of QT révolution, vaporisation and arrhythmogenesis: dévotion to preclinical cardiovascular safety pharmacology of an NCE.
J. Camm (U.K.): Strategies to maximise detection risk of QT interval révolution before the appoval of an NCE: clinical trial designs, techniques of measurements and pitfalls.
R. Shah (U.K.): Regulatory dilemmas and implications for approval and labelling of an NCE.